New hope for duchenne: experimental drug aims to restore muscle protein
NCT ID NCT06053814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a drug called NS-050/NCNP-03 in 20 boys with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The drug is designed to skip a faulty section of the dystrophin gene, allowing the body to produce a shorter but still functional version of the dystrophin protein, which is essential for muscle strength. The study will first assess safety and dosing, then measure changes in dystrophin levels and muscle function over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NS-050/NCNP-03 (a drug designed to skip exon 50 of the dystrophin gene, helping produce a shorter but functional dystrophin protein)
What this could lead to
If successful, this drug could help boys with a specific DMD mutation produce a working version of dystrophin, potentially slowing muscle decline and improving quality of life.
What could go wrong
This is an early phase 1/2 trial with only 20 participants, so safety and effectiveness are not yet proven. The drug may not produce enough dystrophin to make a meaningful difference, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alberta Children's Hospital
Calgary, Alberta, Canada
-
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
-
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
-
Children's Hospital Colorado
Aurora, Colorado, 80011, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Hyogo Medical University Hospital
Nishinomiya, Hyōgo, 663-8501, Japan
-
Istanbul University
Istanbul, Turkey (Türkiye)
-
London Health Sciences Centre
London, Ontario, Canada
-
Miyagi Children's Hospital
Sendai, Miyagi, 989-3126, Japan
-
NHO Osaka Toneyama Medical Center
Toyonaka, Osaka, 560-8552, Japan
-
National Center of Neurology and Psychiatry
Kodaira, Tokyo, 187-8551, Japan
-
National Hospital Organization Nagara Medical Center
Nagara, Gifu, 502-8558, Japan
-
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
University of Kansas Medical Center
Kansas City, Kansas, 66103, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey (Türkiye)